NRX Pharmaceuticals (NRXP) said Monday that it has completed 12 months of demonstrating the stability of its first manufactured lot of NRX-100, or Ketamine, at Nephron Pharmaceuticals.
NRX Pharmaceuticals said reaching the stability milestone will help support its submission of a new drug application with the US Food and Drug Administration to use intravenous ketamine to treat suicidal depression.
The biopharmaceutical company also said the NDA filing for NRX-100 "is on track for 2024."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments